Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Hairy Cell Leukemia

Agnieszka Janus  1 , Tadeusz Robak  1   2
Weijie Li  1
, editors.
In: Leukemia [Internet]. Brisbane (AU): Exon Publications; 2022 Oct 16. Chapter 3.
Affiliations
Review

Hairy Cell Leukemia

Agnieszka Janus et al.

Excerpt

Hairy cell leukemia is a rare, indolent, chronic lymphoid neoplasm originating from a mature B lymphocyte. Diagnosis is based on hairy cell morphology, immunological phenotype by flow cytometry and/or immunohistochemistry in trephine biopsy, and the presence of BRAFV600E somatic mutation. In the classic form of the disease, the purine nucleoside analogues pentostatin and cladribine are recommended for the first-line treatment. These agents induce durable and unmaintained complete response in more than 70% of cases and up to 35% of patients demonstrate overall survival longer than 20 years. When rituximab is combined with cladribine in early relapse, complete response can be achieved in 89–100% of patients, with a three-year risk of relapse of only 7%. More recently, several new drugs have been introduced for the treatment of patients with hairy cell leukemia. Clinical trials have confirmed that the immunotoxin moxetumomab pasudotox, BRAF kinase inhibitors (vemurafenib and dabrafenib), and the Bruton kinase inhibitor ibrutinib are useful agents in the treatment of patients who are refractory to purine analogs.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors declare no potential conflicts of interest with respect to research, authorship and/or publication of this manuscript.

References

    1. Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017;129(5):553–60. https://doi.org/10.1182/blood-2016-01-689422 . - DOI - PMC - PubMed
    1. Robak T, Matutes E, Catovsky D, Zinzani PL, Buske C, ESMO Guidelines Committee Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v100-7. https://doi.org/10.1093/annonc/mdv200 . - DOI - PubMed
    1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90. https://doi.org/10.1182/blood-2016-01-643569 . - DOI - PMC - PubMed
    1. Maitre E, Tomowiak C, Lebecque B, Bijou F, Benabed K, Naguib D, et al. Deciphering genetic alterations of hairy cell leukemia and hairy cell leukemia-like disorders in 98 patients. Cancers (Basel) 2022;14(8):1904. https://doi.org/10.3390/cancers14081904 . - DOI - PMC - PubMed
    1. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):1720–48. https://doi.org/10.1038/s41375-022-01620-2 . - DOI - PMC - PubMed

LinkOut - more resources